Published on Wednesday, 07 March 2012 00:00
Written by Gregory Fowler
Provided by HIVandHepatitis.com
New therapies are leading to a "huge sea change" in the way infectious disease doctors are thinking about hepatitis C, Douglas Dieterich suggested at a press conference at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
New therapies are leading to a "huge sea change" in the way infectious disease doctors are thinking about hepatitis C, Douglas Dieterich suggested at a press conference at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Joining Dieterich on the panel, David Thomas drew similarities to the state of HIV treatment in the 1990s before the advent of HIV protease inhibitors and effective combination therapy.
Mark Sulkowski emphasized the need for guidelines for treating HIV/HCV coinfected patients, noting that new week 12 sustained virological response data presented at the meeting "truly are cutting-edge." The latest data, he said, allay concerns about post-treatment relapse, while Dieterich noted that worries about worse side effects among coinfected people have not been confirmed.
Finally, Edward Gane expressed optimism about seeing interferon-free regimens within the next 5 years.
3/7/12
Reference
Press conference. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, WA. March 6, 2012.
Source
No comments:
Post a Comment